Watson Stuart, Gallagher Peter, Smith Margaret S, Young Allan H, Ferrier I Nicol
The Stanley Research Centre, School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, UK.
Psychoneuroendocrinology. 2007 Jun;32(5):464-9. doi: 10.1016/j.psyneuen.2007.02.010. Epub 2007 Apr 17.
The impact of lithium on arginine vasopressin (AVP) release has implications for our understanding of the pathophysiology and treatment of mood disorders and for the interpretation of neuroendocrine studies. In this secondary analysis of neuroendocrine, data from 23 patients with chronic major depressive disorder, 41 patients with bipolar disorder and 18 healthy controls, we examine the relationship between lithium therapy, AVP levels and the cortisol response to the dexamethasone/corticotropin-releasing hormone (dex/CRH) test. These data demonstrate that patients taking lithium have elevated post-dexamethasone AVP levels compared to both healthy controls and patients not on lithium.
锂对精氨酸加压素（AVP）释放的影响，对于我们理解情绪障碍的病理生理学和治疗以及解释神经内分泌研究具有重要意义。在这项对神经内分泌数据的二次分析中，我们纳入了23例慢性重度抑郁症患者、41例双相情感障碍患者和18名健康对照者，研究锂治疗、AVP水平与地塞米松/促肾上腺皮质激素释放激素（dex/CRH）试验中皮质醇反应之间的关系。这些数据表明，与健康对照者和未服用锂的患者相比，服用锂的患者在服用地塞米松后的AVP水平升高。
